What is Reminyl?
Reminyl, with the generic name of galantamine hydrobromide, is marketed by Ortho-McNeil, a subsidiary of Johnson and Johnson. Galantamine has recently had its name changed in 2005 from Reminyl to Razadyne, in an effort to avoid confusion with the diabetes drug Amaryl. The name was changed after several instances of prescribing and dispensing errors were reported. Reminyl is a member of a class of drugs known as acetylcholinesterase inhibitors. Reminyl is designed to treat patients who suffer from mild to moderate cases of Alzheimer's disease. Alzheimer's disease is a condition where the patient has trouble with memory and thinking due to dying nerve cells in the brain. Alzheimer's is an extremely debilitating disease that affects millions of people and is also believed to be the leading cause of dementia. Reminyl is designed to work by protecting the chemical messenger known as acetylcholine from being destroyed. Acetylcholine is the chemical messenger responsible for cognitive skills and memory.
 Contact us regarding Reminyl; attorney consultations are free.
Reminyl FDA Warning
The FDA has asked Johnson and Johnson to add a new warning to the labeling of Reminyl concerning recent findings from clinical studies. According to the FDA, they along with additional international health authorities are reviewing the safety of Reminyl; after results from two clinical studies reported that the patients taking the drug had a higher rate of death than another group taking a placebo. These two clinical studies were both two-year trials that involved approximately 2,000 patients in 16 different countries. These two clinical studies were designed to examine whether Reminyl could be used in order to slow the progression to dementia in patients with mild cognitive impairment. According to the FDA individuals with mild cognitive impairment demonstrate isolated memory impairment greater than expected for their age and education. Mild cognitive impairment is less severe than Alzheimer's disease, but still involves memory loss, and most patients with mild cognitive impairment may later develop Alzheimer's disease. A total of 15 of the patients taking Reminyl during the study died either while taking the drug or within 30 days after discontinuation of the drug. On the other hand the patients in the placebo group only suffered only 5 deaths. The causes of death for all of those who died were from causes that are common in the elderly population including heart attack, sudden death and stroke.
Questions and Consultations
If you or a family member has used the prescription drug Reminyl and noticed adverse side effects, you should contact a physician immediately. If you would like to discuss your rights, are interested in more information on Reminyl litigation, or if you have information about the cases that you would like to share with us, please fill out the short evaluation form below and a member of Seeger Weiss LLP's experienced staff will call you to discuss your potential rights concerning Reminyl. Attorney consultations incur no obligation on your part and all initial consultations are free of charge and do not create an attorney-client relationship. Seeger Weiss LLP has office locations in both New York and New Jersey and its attorneys practice in courts throughout the country.
Link To Lawyer Seek's Reminyl Content:
<a href='http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Reminyl-P85/'>Reminyl: Lawyer Seek</a> |
|
